Article

Analysis of BRAF inhibitor resistance in melanoma cells

2020-01-01

Abstract excerpt

Malignant melanoma is a highly aggressive and metastatic form of skin cancer with more than 2500 skin cancer related deaths in 2014 in the UK alone. This type of melanoma has a high prevalence of BRAF mutations (90% BRAFV600E) which causes an overactive MAPK signalling cascade leading to excessive proliferation, survival and enhanced angiogenic potential. Vemurafenib and dabrafenib are BRAFV600E specific kinase in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 39d52bf5-8ee0-583a-ad3e-33964e873368
DOI: 10.17638/03106181

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Analysis of BRAF inhibitor resistance in melanoma cellsDOI 10.17638/03106181Read

Resistance to BRAF-targeted therapy in melanoma.Semantic proximity Read

Overcoming resistance to BRAF inhibitorsSemantic proximity Read

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read

Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell linesSemantic proximity Read

Which drug, and when, for patients with BRAF-mutant melanoma?Semantic proximity Read

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read

Targeted therapy in BRAF‑mutant melanoma: Advances and challenges (Review).Semantic proximity Read

The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib.Semantic proximity Read

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.Semantic proximity Read

Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.Semantic proximity Read

MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.Semantic proximity Read